Yang, Ke
University Health Network · Baylor College of Medicine · University of Zurich · Toronto General Hospital · Hospital Italiano de Buenos Aires · CymaBay Therapeutics (United States) · University of California Davis Medical Center · University of California, Davis · The University of Texas Southwestern Medical Center
2 papers on CoChatORCID 0000-0002-1870-1134
Most cited papers
- Verified
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 286
- Verified
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 39
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free